FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.27), $0.03 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $130.76 million versus the consensus estimate of $135.6 million.
GUIANCE:
2022 Financial Guidance
NUPLAZID net sales guidance in Parkinsons... More
